Hyaluronic acid (HA) is a critical viscoelastic polymer within synovial fluid and cartilage matrix, responsible for lubrication, shock absorption, and structural hydration.

In osteoarthritis (OA) and inflammatory joint conditions, the decline of endogenous HA in both concentration and molecular weight compromises joint resilience, leading to pain, stiffness, and impaired mobility.

Oral supplementation with medium molecular weight HA (200-800 kDa), particularly the 400 kDa form, has been clinically validated to restore synovial integrity, modulate inflammation, and improve functional outcomes.

At a dosage of 50 mg/day, HA engages CD44 receptors to stimulate endogenous HA synthesis, enhance synovial viscosity, and buffer inflammatory cytokines (IL-1β, TNF-α, PGE₂).

Clinical trials consistently report significant improvements in WOMAC scores, gait stability, and mobility with medium-MW HA supplementation, while international guidelines (OARSI, ESCEO, EFSA, JCN) endorse its long-term safety and efficacy.

Keyora JointOra 5 in 1 incorporates 50 mg/day of 400 kDa HA, strategically positioned to deliver optimal bioavailability, synovial targeting, and viscoelastic support.

Within a multi-ingredient matrix including UC-II, glucosamine sulfate, chondroitin sulfate, and vitamin D₃, HA functions as the central lubrication hub, synergizing with structural and immunomodulatory agents to reinforce joint cushioning, reduce inflammatory burden, and support cartilage elasticity.

Target populations include individuals with synovial fluid insufficiency, morning stiffness, high mechanical joint load, or early degenerative changes.

Thus, 400 kDa oral HA represents a clinically grounded, safe, and precision-dosed intervention for long-term joint resilience and comfort.